GENinCode (LON:GENI) Stock Price Up 12.7% – Still a Buy?

GENinCode Plc (LON:GENI)’s share price rose 12.7% on Wednesday . The company traded as high as GBX 3.23 and last traded at GBX 3.21. Approximately 448,167 shares were traded during mid-day trading, a decline of 46% from the average daily volume of 833,580 shares. The stock had previously closed at GBX 2.85.

GENinCode Price Performance

The stock has a fifty day simple moving average of GBX 2.88 and a 200-day simple moving average of GBX 2.44. The company has a market capitalization of £8.61 million, a PE ratio of -1.28 and a beta of 0.66. The company has a current ratio of 2.60, a quick ratio of 15.89 and a debt-to-equity ratio of 9.28.

GENinCode (LON:GENI) last released its quarterly earnings data on Tuesday, September 30th. The company reported GBX (1.19) EPS for the quarter. GENinCode had a negative net margin of 228.70% and a negative return on equity of 289.74%. Equities analysts anticipate that GENinCode Plc will post -7.1299999 earnings per share for the current year.

GENinCode Company Profile

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies.